Long intergenic non-protein coding RNA 574 (LINC00574)

Long intergenic non-protein coding RNA 574 (LINC00574) is a member of the long non-coding RNA (lncRNA) family, specifically classified as a long intergenic non-coding RNA (lincRNA)[1][7]. These RNAs are longer than 200 nucleotides and are not translated into protein. LINC00574 is transcribed from regions between protein-coding genes and is distinct from antisense or intronic lncRNAs[1][7]. Like other lincRNAs, LINC00574 is implicated in the regulation of gene expression at various levels, including chromatin modification, transcriptional regulation, and organization of nuclear structure[1][3]. It is sometimes referred to as "chemoresistance-associated lncRNA" (CRALA), indicating a reported association with chemotherapy resistance in cancer—particularly in colorectal cancer—although detailed mechanisms and validated drug interactions remain to be clarified[2]. No direct therapeutic drugs target LINC00574, and there are no recognized safety concerns or clinical biomarkers established for its use. Its principal relevance is as a non-coding gene involved in the modulation of cancer cell biology and chemoresistance[2]. Additional notes: - LINC00574 is not a protein, receptor, or classical drug target but rather an RNA molecule with regulatory functions[1][7]. - Some literature refers to it in the context of chemoresistance, but there is no evidence that it is an established therapeutic target with approved drugs or clinical biomarker assays[2]. - "CRALA" is frequently referenced as “chemoresistance-associated lncRNA,” but this is a functional alias, not a molecular classification or canonical name. If more detailed mechanistic or disease-association information for LINC00574 specifically (e.g., experimentally validated target genes or pathways) becomes available, it might support inclusion as a biomarker or therapeutic target, but current curated sources do not list it as such[2].

Other names

C6orf208FLJ13162dJ182D15.1CRALAchemoresistance-associated lncRNA